STROBE Statement—Checklist of items that should be included in reports of ***cross-sectional studies***

	Item No	Recommendation	Page & Line No	Section, Paragraph
Title and abstract	1	(*a*) Indicate the study's design with a commonly used term in the title or the abstract	Page 1, line 1–2 Page 3, line 55	Title & Abstract
		(*b*) Provide in the abstract an informative and balanced summary of what was done and what was found	Page 3, line 55–67	Abstract, paragraph 2–4
Introduction				
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	Page 4, line 74–85	Introduction, paragraph 1
Objectives	3	State specific objectives, including any prespecified hypotheses	Page 4, line 85–87	Introduction, paragraph 1
Methods				
Study design	4	Present key elements of study design early in the paper	Page 4–5, line 93–103	Methods, paragraph 1
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	Page 4–5, line 94–100	Methods, paragraph 1
Participants	6	(*a*) Give the eligibility criteria, and the sources and methods of selection of participants	Page 4–5, line 94–100	Methods, paragraph 1
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	Page 6, line 128–150	Methods, paragraph 3–5
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	Page 6, line 128–150	Methods, paragraph 3–5
Bias	9	Describe any efforts to address potential sources of bias	Page 6–7, line 143–152	Methods, paragraph 5
Study size	10	Explain how the study size was arrived at	Page 6–7, line 141–151 Page 7, line 159 –161	Methods, paragraph 5 Results, paragraph 1
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	Page 7, line 154	Methods, paragraph 6

Statistical methods	12	(*a*) Describe all statistical methods, including those used to control for confounding	Page 7, line 154–155	Methods, paragraph 6
		(*b*) Describe any methods used to examine subgroups and interactions	N/A	N/A
		(*c*) Explain how missing data were addressed	Page 7, line 161	Results, paragraph 1
		(*d*) If applicable, describe analytical methods taking account of sampling strategy	N/A	N/A
		(*e*) Describe any sensitivity analyses	N/A	N/A
Results				
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Page 7, line 159–161	Results, paragraph 1
		(b) Give reasons for non-participation at each stage	Page 7, line 160–161	Results, paragraph 1
		(c) Consider use of a flow diagram	N/A	
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders	Page 7, line 161–168	Results, paragraph 1
		(b) Indicate number of participants with missing data for each variable of interest	N/A	N/A
Outcome data	15*	Report numbers of outcome events or summary measures	Page 7–8, line 171–185	Results, paragraph 2–3
Main results	16	(*a*) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	N/A	N/A
		(*b*) Report category boundaries when continuous variables were categorized	N/A	N/A
		(*c*) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period	N/A	N/A

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	N/A	N/A
Discussion				
Key results	18	Summarise key results with reference to study objectives	Page 8–10, line 198–233	Discussion, paragraph 2–4
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	Page 11, line 253–259	Limitations, paragraph 1
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	Page 11, line 248–250	Conclusion, paragraph 1
Generalisability	21	Discuss the generalisability (external validity) of the study results	Page 11, line 253–259	Limitations, paragraph 1
Other information				
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	N/A	N/A

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.

Article information: https://dx.doi.org/10.21037/ajo-23-30
*As the checklist was provided upon initial submission, the page number/line number reported may be changed due to copyediting and may not be referable in the published version. In this case, the section/paragraph may be used as an alternative reference.